Gene therapy

Gene Therapy

Volumn , Issue , 2010, Pages 1-303

  Giacca, Mauro ^a  

^a INTERNATIONAL CENTRE FOR GENETIC ENGINEERING AND BIOTECHNOLOGY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84920095141     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-88-470-1643-9     Document Type: Book

References (419)

1. Couzin-Frankel J (2009) Genetics. The promise of a cure: 20 years and counting. Science 324:1504-1507
2. Ledley FD (1995) Nonviral gene therapy: the promise of genes as pharmaceutical products. Hum Gene Ther 6:1129-1144
3. Miller DA (1992) Human gene therapy comes of age. Nature 357:455-460
4. Pearson H (2009) Human genetics: one gene, twenty years. Nature 460:164-169
5. Ross G, Erickson R, Knorr D et al (1996) Gene therapy in the United States: a five-year status report. Hum Gene Ther 7:1781-1790
6. Thomas CE, Ehrhardt A, Kay MA (2003) Progress and problems with the use of viral vectors for gene therapy. Nat Rev Genet 4:346-358
7. Zaldumbide A, Hoeben RC (2007) How not to be seen: immune-evasion strategies in gene therapy. Gene Ther 15:239-246
8. Baron U, Bujard H (2000) Tet repressor-based system for regulated gene expression in eukaryo - tic cells: principles and advances. Methods Enzymol 327:401-421
9. Brown BD, Naldini L (2009) Exploiting and antagonizing microRNA regulation for therapeutic and experimental applications. Nat Rev Genet 10:578-585
10. Clackson T (1997) Controlling mammalian gene expression with small molecules. Curr Opin Chem Biol 1:210-218
11. Duca M, Vekhoff P, Oussedik K et al (2008) The triple helix: 50 years later, the outcome. Nucleic Acids Res 36:5123-5138
12. Guo ZS, Li Q, Bartlett DL, Yang J Y, Fang B (2008) Gene transfer: the challenge of regulated gene expression. Trends Mol Med 14:410-418
13. Harvey DM, Caskey CT (1998) Inducible control of gene expression: prospects for gene therapy. Curr Opin Chem Biol 2:512-518
14. Lobato MN, Rabbitts TH (2003) Intracellular antibodies and challenges facing their use as therapeutic agents. Trends Mol Med 9:390-396
15. Magnenat L, Schwimmer LJ, Barbas CF (2008) Drug-inducible and simultaneous regulation of endogenous genes by single-chain nuclear receptor-based zinc-finger transcription factor gene switches. Gene Ther 15:1223-1232
16. Muyldermans S, Cambillau C, Wyns L (2001) Recognition of antigens by single-domain antibody fragments: the superfluous luxury of paired domains. Trends Biochem Sci 26:230-235
17. Toniatti C, Bujard H, Cortese R, Ciliberto G (2004) Gene therapy progress and prospects: transcription regulatory systems. Gene Ther 11:649-657
18. Baum C, Margison GP, Eckert H-G et al (1996) Gene transfer to augment the therapeutic index of anticancer chemotherapy. Gene Ther 3:1-3
19. Brown BD, Gentner B, Cantore A et al (2007) Endogenous microRNA can be broadly exploited to regulate transgene expression according to tissue, lineage and differentiation state. Nat Biotechnol 25:1457-1467
20. Gossen M, Bujard H (1992) Tight control of gene expression in mammalian cells by tetracyclineresponsive promoters. Proc Natl Acad Sci USA 89:5547-5551
21. Lobato MN, Rabbitts TH (2003) Intracellular antibodies and challenges facing their use as therapeutic agents. Trends Mol Med 9:390-396
22. Meyer-Ficca ML, Meyer RG, Kaiser H et al (2004) Comparative analysis of inducible expression systems in transient transfection studies. Anal Biochem 334:9-19
23. No D, Yao TP, Evans RM (1996) Ecdysone-inducible gene expression in mammalian cells and transgenic mice. Proc Natl Acad Sci USA 93:3346-3351
24. Weber W, Fussenegger M (2006) Pharmacologic transgene control systems for gene therapy. J Gene Med 8:535-556
25. Brown BD, Naldini L (2009) Exploiting and antagonizing microRNA regulation for therapeutic and experimental applications. Nat Rev Genet 10:578-585
26. Carthew RW, Sontheimer EJ (2009) Origins and mechanisms of miRNAs and siRNAs. Cell 136:642-655
27. Castanotto D, Rossi JJ (2009) The promises and pitfalls of RNA-interference-based therapeutics. Nature 457:426-433
28. Duca M, Vekhoff P, Oussedik K et al (2008) The triple helix: 50 years later, the outcome. Nucleic Acids Res 36:5123-5138
29. Dykxhoorn DM, Palliser D, Lieberman J (2006) The silent treatment: siRNAs as small molecule drugs. Gene Ther 13:541-552
30. Fichou Y, Férec C (2006) The potential of oligonucleotides for therapeutic applications. Trends Biotechnol 24:563-570
31. Hannon GJ (2002) RNA interference. Nature 418:244-251
32. Opalinska JB, Gewirtz AM (2002) Nucleic-acid therapeutics: basic principles and recent applications. Nat Rev Drug Discov 1:503-514
33. Que-Gewirth NS, Sullenger BA (2007) Gene therapy progress and prospects: RNA aptamers. Gene Ther 14:283-291
34. Rao DD, Vorhies JS, Senzer N, Nemunaitis J (2009) siRNA vs. shRNA: similarities and differences. Adv Drug Deliv Rev 61:746-759
35. Ryther RC, Flynt AS, Phillips JA 3rd, Patton JG (2005) siRNA therapeutics: big potential from small RNAs. Gene Ther 12:5-11
36. Shi Y (2003) Mammalian RNAi for the masses. Trends Genet 19:9-12
37. Sioud M, Iversen PO (2005) Ribozymes, DNAzymes and small interfering RNAs as therapeutics. Curr Drug Targets 6:647-653
38. Stevenson M (2004) Therapeutic potential of RNA interference. N Engl J Med 351:1772-1777
39. Tuschl T (2002) Expanding small RNA interference. Nat Biotechnol 20:446-448
40. Wagner RW (1994) Gene inhibition using antisense oligodeoxynucleotides. Nature 372:333-335
41. Wall NR, Shi Y (2003) Small RNA: can RNA interference be exploited for therapy? Lancet 362:1401-1403
42. Zentilin L, Giacca M (2004) In vivo transfer and expression of genes coding for short interfering RNAs. Curr Pharm Biotechnol 5:341-347
43. Bertrand E, Castanotto D, Zhou C et al (1997) The expression cassette determines the functional activity of ribozymes in mammalian cells by controlling their intracellular localization. RNA 3:75-88
44. Brummelkamp TR, Bernards R, Agami R (2002) A system for stable expression of short interfering RNAs in mammalian cells. Science 296:550-553
45. De Fougerolles AR (2008) Delivery vehicles for small interfering RNA in vivo. Hum Gene Ther 19:125-132
46. Dollins CM, Nair S, Sullenger BA (2008) Aptamers in immunotherapy. Hum Gene Ther 19:443-450
47. Fedor MJ (2000) Structure and function of the hairpin ribozyme. J Mol Biol 297:269-291
48. Gleave ME, Monia BP (2005) Antisense therapy for cancer. Nat Rev Cancer 5:468-479
49. Good PD, Krikos AJ, Li SX et al (1997) Expression of small, therapeutic RNAs in human cell nuclei. Gene Ther 4:45-54
50. Elmen J, Lindow M, Schutz S et al (2008) LNA-mediated microRNA silencing in non-human primates. Nature 452:896-899
51. James W, Al-Shamkhani A (1995) RNA enzymes as tools for gene ablation. Curr Opin Biotechnol 6:44-49
52. Krutzfeldt J, Rajewsky N, Braich R et al (2005) Silencing of microRNAs in vivo with 'antagomirs'. Nature 438:685-689
53. Lim LP, Glasner ME, Yekta S et al (2003) Vertebrate microRNA genes. Science 299:1540
54. Matteucci MD, Wagner RW (1996) In pursuit of antisense. Nature 384:20-22
55. Mendoza-Maldonado R, Zentilin L, Giacca M (2001) Purging of chronic myelogenous leukemia cells by retrovirally expressed anti-bcr/abl ribozymes with specific celluar compartmentalization. Cancer Gene Ther 9:71-86
56. Mishra PK, Tyagi N, Kumar M, Tyagi SC (2009) MicroRNAs as a therapeutic target for cardiovascular disease. J Cell Mol Med 13:778-789
57. Paddison PJ, Caudy AA, Hannon GJ (2002) Stable suppression of gene expression by RNAi in mammalian cells. Proc Natl Acad Sci U S A 99:1443-1448
58. Prislei S, Buonomo SB, Michienzi A, Bozzoni I (1997) Use of adenoviral VAI small RNA as a carrier for cytoplasmic delivery of ribozymes. RNA 3:677-687
59. Reynolds A, Leake D, Boese Q et al (2004) Rational siRNA design for RNA interference. Nat Biotechnol 22:326-330
60. Rossi JJ (2008) Expression strategies for short hairpin RNA interference triggers. Hum Gene Ther 19:313-317
61. Scherer LJ, Rossi JJ (2003) Approaches for the sequence-specific knockdown of mRNA. Nat Biotechnol 21:1457-1465
62. Seidman MM, Glazer PM (2003) The potential for gene repair via triple helix formation. J Clin Invest 112:487-494
63. Soutschek J, Akinc A, Bramlage B et al (2004) Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature 432:173-178
64. Stein CA, Chen YC (1993) Antisense oligonucleotides as therapeutic agents: Is the bullet really magical? Science 261:1004-1012
65. Suarez Y, Sessa WC (2009) MicroRNAs as novel regulators of angiogenesis. Circ Res 104:442-454
66. Thompson JD, Macejak D, Couture L, Stinchcomb DT (1995) Ribozymes in gene therapy. Nat Med 1:277-278
67. Weng DE, Masci PA, Radka SF et al (2005) A phase I clinical trial of a ribozyme-based angiogenesis inhibitor targeting vascular endothelial growth factor receptor-1 for patients with refractory solid tumors. Mol Cancer Ther 4:948-955
68. Xia H, Mao Q, Paulson HL, Davidson BL (2002) siRNA-mediated gene silencing in vitro and in vivo. Nat Biotechnol 20:1006-1010
69. Conner SD, Schmid SL (2003) Regulated portals of entry into the cell. Nature 422:37-44
70. Doherty GJ, McMahon HT (2009) Mechanisms of endocytosis. Annu Rev Biochem 78:857-902
71. Sandvig K, Van Deurs B (2005) Delivery into cells: lessons learned from plant and bacterial toxins. Gene Ther 12:865-872
72. Kerr MC, Teasdale RD (2009) Defining macropinocytosis. Traffic 10:364-371
73. Kirkham M, Parton RG (2005) Clathrin-independent endocytosis: new insights into caveolae and non-caveolar lipid raft carriers. Biochim Biophys Acta 1745:273-286
74. Medina-Kauwe LK (2007) "Alternative" endocytic mechanisms exploited by pathogens: new avenues for therapeutic delivery? Adv Drug Deliv Rev 59:798-809
75. Nichols B (2003) Caveosomes and endocytosis of lipid rafts. J Cell Sci 116:4707-4714
76. Pelkmans L, Puntener D, Helenius A (2002) Local actin polymerization and dynamin recruitment in SV40-induced internalization of caveolae. Science 296:535-539
77. Plemper RK, Wolf DH (1999) Retrograde protein translocation: ERADication of secretory proteins in health and disease. Trends Biochem Sci 24:266-270
78. Roth MG (2006) Clathrin-mediated endocytosis before fluorescent proteins. Nat Rev Mol Cell Biol 7:63-68
79. Torgersen ML, Skretting G, Van Deurs B, Sandvig K (2001) Internalization of cholera toxin by different endocytic mechanisms. J Cell Sci 114:3737-3747
80. Braun S (2008) Muscular gene transfer using nonviral vectors. Curr Gene Ther 8:391-405
81. Herweijer H, Wolff JA (2003) Progress and prospects: naked DNA gene transfer and therapy. Gene Ther 10:453-458
82. Frenkel V (2008) Ultrasound mediated delivery of drugs and genes to solid tumors. Adv Drug Deliv Rev 60:1193-1208
83. Hynynen K (2008) Ultrasound for drug and gene delivery to the brain. Adv Drug Deliv Rev 60:1209-1217
84. Wells DJ (2004) Gene therapy progress and prospects: electroporation and other physical methods. Gene Ther 11:1363-1369
85. Andre F, Mir LM (2004) DNA electrotransfer: its principles and an updated review of its therapeutic applications. Gene Ther 11 [Suppl 1]: S33-42
86. Bigey P, Bureau MF, Scherman D (2002) In vivo plasmid DNA electrotransfer. Curr Opin Biotechnol 13:443-447
87. Hagstrom JE (2003) Plasmid-based gene delivery to target tissues in vivo: the intravascular approach. Curr Opin Mol Ther 5:338-344
88. Heller LC, Heller R (2006) In vivo electroporation for gene therapy. Hum Gene Ther 17:890-897
89. Lewis DL, Wolff JA (2007) Systemic siRNA delivery via hydrodynamic intravascular injection. Adv Drug Deliv Rev 59:115-123
90. Mennuni C, Calvaruso F, Zampaglione I et al (2002) Hyaluronidase increases electrogene transfer efficiency in skeletal muscle. Hum Gene Ther 13:355-365
91. Mir LM (2008) Application of electroporation gene therapy: past, current, and future. Methods Mol Biol 423:3-17
92. Newman CM, Bettinger T (2007) Gene therapy progress and prospects: ultrasound for gene transfer. Gene Ther 14:465-475
93. Reed SD, Li S (2009) Electroporation advances in large animals. Curr Gene Ther (in press)
94. Stein U, Walther W, Stege A et al (2008) Complete in vivo reversal of the multidrug resistance phenotype by jet-injection of anti-MDR1 short hairpin RNA-encoding plasmid DNA. Mol Ther 16:178-186
95. Walther W, Siegel R, Kobelt D et al (2008) Novel jet-injection technology for nonviral intratumoral gene transfer in patients with melanoma and breast cancer. Clin Cancer Res 14:7545-7553
96. Walther W, Stein U, Fichtner I et al (2001) Nonviral in vivo gene delivery into tumors using a novel low volume jet-injection technology. Gene Ther 8:173-180
97. Walther W, Stein U, Fichtner I et al (2002) Intratumoral low-volume jet-injection for efficient nonviral gene transfer. Mol Biotechnol 21:105-115
98. Beerens AM, Al Hadithy AF, Rots MG, Haisma HJ (2003) Protein transduction domains and their utility in gene therapy. Curr Gene Ther 3:486-494
99. Elouahabi A, Ruysschaert JM (2005) Formation and intracellular trafficking of lipoplexes and polyplexes. Mol Ther 11:336-347
100. Fittipaldi A, Giacca M (2005) Transcellular protein transduction using the Tat protein of HIV-1. Adv Drug Deliv Rev 57:597-608
101. Giacca M (2004) The HIV-1 Tat protein: a multifaceted target for novel therapeutic opportunities. Curr Drug Targets Immune Endocr Metabol Disord 4:277-285
102. Park TG, Jeong JH, Kim SW (2006) Current status of polymeric gene delivery systems. Adv Drug Deliv Rev 58:467-486
103. Van Dillen IJ, Mulder NH, Vaalburg W et al (2002) Influence of the bystander effect on HSV-tk/GCV gene therapy. A review. Curr Gene Ther 2:307-322
104. Vile RG, Russell SJ, Lemoine NR (2000) Cancer gene therapy: hard lessons and new courses. Gene Ther 7:2-8
105. Wasungu L, Hoekstra D (2006) Cationic lipids, lipoplexes and intracellular delivery of genes. J Control Release 116:255-264
106. Dass CR (2004) Lipoplex-mediated delivery of nucleic acids: factors affecting in vivo transfection. J Mol Med 82:579-591
107. Dincer S, Turk M, Piskin E (2005) Intelligent polymers as nonviral vectors. Gene Ther 12 [Suppl 1]: S139-145
108. Dufes C, Uchegbu IF, Schatzlein AG (2005) Dendrimers in gene delivery. Adv Drug Deliv Rev 57:2177-2202
109. Duncan R, Izzo L (2005) Dendrimer biocompatibility and toxicity. Adv Drug Deliv Rev 57:2215-2237
110. Fittipaldi A, Giacca M (2005) Transcellular protein transduction using the Tat protein of HIV-1. Adv Drug Deliv Rev 57:597-608
111. Hoekstra D, Rejman J, Wasungu L et al (2007) Gene delivery by cationic lipids: in and out of an endosome. Biochem Soc Trans 35:68-71
112. Lange, A, Mills RE, Lange CJ et al (2007) Classical nuclear localization signals: definition, function, and interaction with importin alpha. J Biol Chem 282:5101-5105
113. Pedroso De Lima MC, Simoes S, Pires P et al (2001) Cationic lipid-DNA complexes in gene delivery: from biophysics to biological applications. Adv Drug Deliv Rev 47:277-294
114. Rainov NG (2000) A phase III clinical evaluation of herpes simplex virus type 1 thymidine kinase and ganciclovir gene therapy as an adjuvant to surgical resection and radiation in adults with previously untreated glioblastoma multiforme. Hum Gene Ther 11:2389-2401
115. Ram Z, Culver KW, Oshiro EM et al (1997) Therapy of malignant brain tumors by intratumoral implantation of retroviral vector-producing cells. Nat Med 3:1354-1361
116. Svenson S (2009) Dendrimers as versatile platform in drug delivery applications. Eur J Pharm Biopharm 71:445-462
117. Trask TW, Trask RP, Aguilar-Cordova E et al (2000) Phase I study of adenoviral delivery of the HSV-tk gene and ganciclovir administration in patients with current malignant brain tumors. Mol Ther 1:195-203
118. Wolff JA, Rozema DB (2008) Breaking the bonds: non-viral vectors become chemically dynamic. Mol Ther 16:8-15
119. Zuhorn IS, Engberts JB, Hoekstra D (2007) Gene delivery by cationic lipid vectors: overcoming cellular barriers. Eur Biophys J 36:349-362
120. Bessis N, Garcia Cozar FJ, Boissier MC (2004) Immune responses to gene therapy vectors: influence on vector function and effector mechanisms. Gene Ther 11 [Suppl 1]: S10-17
121. Bestor TH (2000) Gene silencing as a threat to the success of gene therapy. J Clin Invest 105:409-411
122. Chang AH, Sadelain M (2007) The genetic engineering of hematopoietic stem cells: the rise of lentiviral vectors, the conundrum of the ltr, and the promise of lineage-restricted vectors. Mol Ther 15:445-456
123. Coffin JM, Hughes H, Varmus HE (1997) Retroviruses. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, NY, USA
124. Daniel R, Smith JA (2008) Integration site selection by retroviral vectors: molecular mechanism and clinical consequences. Hum Gene Ther 19:557-568
125. Kay MA, Glorioso JC, Naldini L (2001) Viral vectors for gene therapy: the art of turning infectious agents into vehicles of therapeutics. Nat Med 7:33-40
126. Knipe DM, Roizman B, Howley PM et al (2006) Fields' virology, 5th edn. Lippincott Williams & Wilkins, Philadelphia, PA, USA
127. Schambach A, Baum C (2008) Clinical application of lentiviral vectors: concepts and practice. Curr Gene Ther 8:474-482
128. St George JA (2003) Gene therapy progress and prospects: adenoviral vectors. Gene Ther 10:1135-1141
129. Thomas CE, Ehrhardt A, Kay MA (2003) Progress and problems with the use of viral vectors for gene therapy. Nat Rev Genet 4:346-358
130. Wu Z, Asokan A, Samulski RJ (2006) Adeno-associated virus serotypes: vector toolkit for human gene therapy. Mol Ther 14:316-327
131. Zentilin L, Giacca M (2008) Adeno-associated virus vectors: versatile tools for in vivo gene transfer. Contrib Nephrol 159:63-77
132. Aghi M, Martuza RL (2005) Oncolytic viral therapies: the clinical experience. Oncogene 24:7802-7816
133. Aiken C (1997) Pseudotyping human immunodeficiency virus type 1 (HIV-1) by the glycoprotein of vesicular stomatitis virus targets HIV-1 entry to an endocytic pathway and suppresses both the requirement for Nef and the sensitivity to cyclosporin A. J Virol 71:5871-5877
134. Alba R, Bosch A, Chillon M (2005) Gutless adenovirus: last-generation adenovirus for gene therapy. Gene Ther 12 [Suppl 1]: S18-27
135. Argnani R, Lufino M, Manservigi M, Manservigi R (2005) Replication-competent herpes simplex vectors: design and applications. Gene Ther 12 [Suppl 1]: S170-177
136. Barnard RJ, Elleder D, Young JA (2006) Avian sarcoma and leukosis virus-receptor interactions: from classical genetics to novel insights into virus-cell membrane fusion. Virology 344:25-29
137. Barquinero J, Eixarch H, Perez-Melgosa M (2004) Retroviral vectors: new applications for an old tool. Gene Ther 11 [Suppl 1]: S3-9
138. Berges BK, Wolfe JH, Fraser NW (2007) Transduction of brain by herpes simplex virus vectors. Mol Ther 15:20-29
139. Berns KI, Linden RM (1995) The cryptic life style of adeno-associated virus. BioEssays 17:237-245
140. Berto E, Bozac A, Marconi P (2005) Development and application of replication-incompetent HSV-1-based vectors. Gene Ther 12 [Suppl 1]: S98-102
141. Brunetti-Pierri N, Ng P (2008) Progress and prospects: gene therapy for genetic diseases with helper-dependent adenoviral vectors. Gene Ther 15:553-560
142. Buning H, Ried MU, Perabo L et al (2003) Receptor targeting of adeno-associated virus vectors. Gene Ther 10:1142-1151
143. Burton EA, Bai Q, Goins WF, Glorioso JC (2002) Replication-defective genomic herpes simplex vectors: design and production. Curr Opin Biotechnol 13:424-428
144. Cereseto A, Giacca M (2004) Integration site selection by retroviruses. AIDS Rev 6:13-20
145. Cervelli T, Palacios JA, Zentilin L et al (2008) Processing of recombinant AAV genomes occurs in specific nuclear structures that overlap with foci of DNA-damage-response proteins. J Cell Sci 121:349-357
146. Chirmule N, Propert K, Magosin S et al (1999) Immune responses to adenovirus and adeno-associated virus in humans. Gene Ther 6:1574-1583
147. Danthinne X, Imperiale MJ (2000) Production of first generation adenovirus vectors: a review. Gene Ther 7:1707-1714
148. Dull T, Zufferey R, Kelly M et al (1998) A third-generation lentivirus vector with a conditional packaging system. J Virol 72:8463-8471
149. Dutheil N, Shi F, Dupressoir T, Linden RM (2000) Adeno-associated virus site-specifically integrates into a muscle-specific DNA region. Proc Natl Acad Sci U S A 97:4862-4866
150. Epstein AL (2005) HSV-1-based amplicon vectors: design and applications. Gene Ther 12 [Suppl 1]: S154-158
151. Flotte TR (2004) Gene therapy progress and prospects: recombinant adeno-associated virus (rAAV) vectors. Gene Ther 11:805-810
152. Flotte TR, Berns KI (2005) Adeno-associated virus: a ubiquitous commensal of mammals. Hum Gene Ther 16:401-407
153. Gao G, Vandenberghe LH, Wilson JM (2005) New recombinant serotypes of AAV vectors. Curr Gene Ther 5:285-297
154. Gregorevic P, Blankinship MJ, Allen JM et al (2004) Systemic delivery of genes to striated muscles using adeno-associated viral vectors. Nat Med 10:828-834
155. Grimm D, Kern A, Rittner K, Kleinschmidt JA (1998) Novel tools for production and purification of recombinant adenoassociated virus vectors Hum. Gene Ther 9:2745-2760
156. Hendrie PC, Russell DW (2005) Gene targeting with viral vectors. Mol Ther 12:9-17
157. Jooss K, Chirmule N (2003) Immunity to adenovirus and adeno-associated viral vectors: implications for gene therapy. Gene Ther 10:955-963
158. Linden RM, Ward P, Giraud C et al (1996) Site-specific integration by adeno-associated virus. Proc Natl Acad Sci U S A 93:11288-11294
159. Liu Q, Muruve DA (2003) Molecular basis of the inflammatory response to adenovirus vectors. Gene Ther 10:935-940
160. Manganaro L, Lusic M, Gutierrez MI et al (2009) Concerted action of cellular JNK and Pin1 restricts HIV-1 genome integration to activated CD4+ T lymphocytes. Nat Med
161. Marconi P, Argnani R, Berto E et al (2008) HSV as a vector in vaccine development and gene therapy. Hum Vaccin 4:91-105
162. McCarty DM, Young SM Jr, Samulski RJ (2004) Integration of adeno-associated virus (AAV) and recombinant AAV vectors. Annu Rev Genet 38:819-845
163. Merten OW, Geny-Fiamma C, Douar AM (2005) Current issues in adeno-associated viral vector production. Gene Ther 12 [Suppl 1]: S51-61
164. Miller AD (1990) Retrovirus packaging cells. Hum Gene Ther 1:5-14
165. Miller AD (1996) Cell-surface receptors for retroviruses and implications for gene transfer. Proc Natl Acad Sci U S A 93:11407-11413
166. Miller DG, Wang PR, Petek LM et al (2006) Gene targeting in vivo by adeno-associated virus vectors. Nature Biotech 24:1022-1026
167. Mueller C, Flotte TR (2008) Clinical gene therapy using recombinant adeno-associated virus vectors. Gene Ther 15:858-863
168. Naldini L, Blomer U, Gallay P et al (1996) In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 272:263-267
169. Nienhuis AW, Dunbar CE, Sorrentino BP (2006) Genotoxicity of retroviral integration in hematopoietic cells. Mol Ther 13:1031-1049
170. Russell DW, Hirata RK (1998) Human gene targeting by viral vectors. Nat Genet 18:325-330
171. Russell WC (2000) Update on adenovirus and its vectors. J Gen Virol 81:2573-2604
172. Russell WC (2009) Adenoviruses: update on structure and function. J Gen Virol 90:1-20
173. Samulski RJ, Berns KI, Tan M, Muzyczka N (1982) Cloning of adeno-associated virus into pBR322: rescue of intact virus from the recombinant plasmid in human cells. Proc Natl Acad Sci USA 79:2077-2081
174. Schroder AR, Shinn P, Chen H et al (2002) HIV-1 integration in the human genome favors active genes and local hotspots. Cell 110:521-529
175. Sinn PL, Sauter SL, McCray PB Jr (2005) Gene therapy progress and prospects: development of improved lentiviral and retroviral vectors: design, biosafety, and production. Gene Ther 12:1089-1098
176. Vasileva A, Jessberger R (2005) Precise hit: adeno-associated virus in gene targeting. Nat Rev Microbiol 3:837-847
177. Vihinen-Ranta M, Suikkanen S, Parrish CR (2004) Pathways of cell infection by parvoviruses and adeno-associated viruses. J Virol 78:6709-6714
178. Wang Z, Zhu T, Qiao C et al (2005) Adeno-associated virus serotype 8 efficiently delivers genes to muscle and heart. Nat Biotechnol 23:321-328
179. Yamamoto T, Tsunetsugu-Yokota Y (2008) Prospects for the therapeutic application of lentivirusbased gene therapy to HIV-1 infection. Curr Gene Ther 8:1-8
180. Zentilin L, Qin G, Tafuro S et al (2000) Variegation of retroviral vector gene expression in myeloid cells. Gene Ther 7:153-166
181. Zufferey R, Dull T, Mandel RJ et al (1998) Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery. J Virol 72:9873-9880
182. Alexander BL, Ali RR, Alton EW et al (2007) Progress and prospects: gene therapy clinical trials (part 1). Gene Ther 14:1439-1447
183. Alton E, Ferrari S, Griesenbach U (2007) Progress and prospects: gene therapy clinical trials (part 2). Gene Ther 14:1555-1563
184. Edelstein ML, Abedi MR, Wixon J (2007) Gene therapy clinical trials worldwide to 2007: an update. J Gene Med 9:833-842
185. Edelstein ML, Abedi MR, Wixon J, Edelstein RM (2004) Gene therapy clinical trials worldwide 1989-2004: an overview. J Gene Med 6:597-602
186. Fischer A, Cavazzana-Calvo M (2008) Gene therapy of inherited diseases. Lancet 371:2044-2047
187. Porteus MH, Connelly JP, Pruett SM (2006) A look to future directions in gene therapy research for monogenic diseases. PLoS Genet 2:e133
188. Relph K, Harrington K, Pandha H (2004) Recent developments and current status of gene therapy using viral vectors in the United Kingdom. BMJ 329:839-842
189. Schenk-Braat EA, Van Mierlo MM, Wagemaker G et al (2007) An inventory of shedding data from clinical gene therapy trials. J Gene Med 9:910-921
190. Ambudkar SV, Kimchi-Sarfaty C, Sauna ZE, Gottesman MM (2003) P-glycoprotein: from genomics to mechanism. Oncogene 22:7468-7485
191. Baker SJ, Rane SG, Reddy EP (2007) Hematopoietic cytokine receptor signaling. Oncogene 26:6724-6737
192. Cavazzana-Calvo M, Fischer A (2007) Gene therapy for severe combined immunodeficiency: are we there yet? J Clin Invest 117:1456-1465
193. Cavazzana-Calvo M, Lagresle C, Hacein-Bey-Abina S, Fischer A (2005) Gene therapy for severe combined immunodeficiency. Annu Rev Med 56:585-602
194. Greenberger JS (2008) Gene therapy approaches for stem cell protection. Gene Ther 15:100-108
195. Hawley RG, Sobieski DA (2002) Of mice and men: the tale of two therapies. Stem Cells 20:275-278
196. Hossle JP, Seger RA, Steinhoff D (2002) Gene therapy of hematopoietic stem cells: strategies for improvement. News Physiol Sci 17:87-92
197. Licht T, Herrmann F, Gottesman MM, Pastan I (1997) In vivo drug-selectable genes: a new concept in gene therapy. Stem Cells 15:104-111
198. Nienhuis AW (2008) Development of gene therapy for blood disorders. Blood 111:4431-4444
199. Sands MS, Davidson BL (2006) Gene therapy for lysosomal storage diseases. Mol Ther 13:839-849
200. Tey SK, Brenner MK (2007) The continuing contribution of gene marking to cell and gene therapy. Mol Ther 15:666-676
201. Thrasher AJ, Gaspar HB, Baum C et al (2006) Gene therapy: X-SCID transgene leukaemogenicity. Nature 443:E5-6; discussion E6-7
202. Zielske SP, Braun SE (2004) Cytokines: value-added products in hematopoietic stem cell gene therapy. Mol Ther 10:211-219
203. Aiuti A, Cattaneo F, Galimberti S et al (2009) Gene therapy for immunodeficiency due to adenosine deaminase deficiency. N Engl J Med 360:447-458
204. Aiuti A, Slavin S, Aker M et al (2002) Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning. Science 296:2410-2413
205. Aiuti A, Vai S, Mortellaro A et al (2002) Immune reconstitution in ADA-SCID after PBL gene therapy and discontinuation of enzyme replacement. Nat Med 8:423-425
206. Alexander IE, Cunningham SC, Logan GJ, Christodoulou J (2008) Potential of AAV vectors in the treatment of metabolic disease. Gene Ther 15:831-839
207. Baum C, Von Kalle C, Staal FJ et al (2004) Chance or necessity? Insertional mutagenesis in gene therapy and its consequences. Mol Ther 9:5-13
208. Beck M (2007) New therapeutic options for lysosomal storage disorders: enzyme replacement, small molecules and gene therapy. Hum Genet 121:1-22
209. Biffi A, Naldini L (2005) Gene therapy of storage disorders by retroviral and lentiviral vectors. Hum Gene Ther 16:1133-1142
210. Bonini C, Bondanza A, Perna SK et al (2007) The suicide gene therapy challenge: how to improve a successful gene therapy approach. Mol Ther 15:1248-1252
211. Brenner MK (1996) Gene marking. Gene Ther 3:278-279
212. Cattoglio C, Facchini G, Sartori D et al (2007) Hot spots of retroviral integration in human CD34+ hematopoietic cells. Blood 110:1770-1778
213. Cavazzana-Calvo M, Hacein-Bey S, De Saint Basile G et al (2000) Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science 288:669-672
214. Cheng SH, Smith AE (2003) Gene therapy progress and prospects: gene therapy of lysosomal storage disorders. Gene Ther 10:1275-1281
215. Dave UP, Jenkins NA, Copeland NG (2004) Gene therapy insertional mutagenesis insights. Science 303:333
216. Deisseroth AB, Zu Z, Claxton D et al (1994) Genetic marking shows that Ph+ cells present in autologous transplants of chronic myelogenous leukemia (CML) contribute to relapse after autologous bone marrow in CML. Blood 83:3068-3076
217. Dinauer MC, Orkin SH (1992) Chronic granulomatous disease. Annu Rev Med 43:117-124
218. Gaspar HB, Bjorkegren E, Parsley K et al (2006) Successful reconstitution of immunity in ADA-SCID by stem cell gene therapy following cessation of PEG-ADA and use of mild preconditioning. Mol Ther 14:505-513
219. Gaspar HB, Parsley KL, Howe S et al (2004) Gene therapy of X-linked severe combined immunodeficiency by use of a pseudotyped gammaretroviral vector. Lancet 364:2181-2187
220. Hacein-Bey-Abina S, Von Kalle C, Schmidt M et al (2003) A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N Engl J Med 348:255-256
221. Hacein-Bey-Abina S, Von Kalle C, Schmidt M et al (2003) LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 302:415-419
222. Hodges BL, Cheng SH (2006) Cell and gene-based therapies for the lysosomal storage diseases. Curr Gene Ther 6:227-241
223. Kohn DB, Sadelain M, Glorioso JC (2003) Occurrence of leukaemia following gene therapy of X-linked SCID. Nat Rev Cancer 3:477-488
224. Muul LM, Tuschong LM, Soenen SL et al (2003) Persistence and expression of the adenosine deaminase gene for 12 years and immune reaction to gene transfer components: long-term results of the first clinical gene therapy trial. Blood 101:2563-2569
225. Ott MG, Schmidt M, Schwarzwaelder K et al (2006) Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1. Nat Med 12:401-409
226. Schwarzwaelder K, Howe SJ, Schmidt M et al (2007) Gammaretrovirus-mediated correction of SCID-X1 is associated with skewed vector integration site distribution in vivo. J Clin Invest 117:2241-2249
227. Shou Y, Ma Z, Lu T, Sorrentino BP (2006) Unique risk factors for insertional mutagenesis in a mouse model of XSCID gene therapy. Proc Natl Acad Sci U S A 103:11730-11735
228. Woods NB, Bottero V, Schmidt M et al (2006) Gene therapy: therapeutic gene causing lymphoma. Nature 440:1123
229. Anson DS, Smith GJ, Parsons DW (2006) Gene therapy for cystic fibrosis airway disease: is clinical success imminent? Curr Gene Ther 6:161-179
230. Flotte TR, Ng P, Dylla DE et al (2007) Viral vector-mediated and cell-based therapies for treatment of cystic fibrosis. Mol Ther 15:229-241
231. Griesenbach U, Alton EW (2009) Gene transfer to the lung: lessons learned from more than 2 decades of CF gene therapy. Adv Drug Deliv Rev 61:128-139
232. Griesenbach U, Geddes DM, Alton EW (2006) Gene therapy progress and prospects: cystic fibrosis. Gene Ther 13:1061-1067
233. O'Sullivan BP, Freedman SD (2009) Cystic fibrosis. Lancet 373:1891-1904
234. Riordan JR (2008) CFTR function and prospects for therapy. Annu Rev Biochem 77:701-726
235. Crystal RG, McElvaney NG, Rosenfeld MA et al (1994) Administration of an adenovirus containing the human CFTR cDNA to the respiratory tract of individuals with cystic fibrosis. Nat Genet 8:42-51
236. Kinsey BM, Densmore CL, Orson FM (2005) Non-viral gene delivery to the lungs. Curr Gene Ther 5:181-194
237. Kremer KL, Dunning KR, Parsons DW, Anson DS (2007) Gene delivery to airway epithelial cells in vivo: a direct comparison of apical and basolateral transduction strategies using pseudotyped lentivirus vectors. J Gene Med 9:362-368
238. Li W, Zhang L, Johnson JS et al (2009) Generation of novel AAV variants by directed evolution for improved CFTR delivery to human ciliated airway epithelium. Mol Ther 17:2067-2077
239. Tagalakis AD, McAnulty RJ, Devaney J et al (2008) A receptor-targeted nanocomplex vector system optimized for respiratory gene transfer. Mol Ther 16:907-915
240. Athanasopoulos T, Graham IR, Foster H, Dickson G (2004) Recombinant adeno-associated viral (rAAV) vectors as therapeutic tools for Duchenne muscular dystrophy (DMD). Gene Ther 11 [Suppl 1]: S109-121
241. Chakkalakal J V, Thompson J, Parks RJ, Jasmin BJ (2005) Molecular, cellular, and pharmacological therapies for Duchenne/Becker muscular dystrophies. FASEB J 19:880-891
242. Foster K, Foster H, Dickson JG (2006) Gene therapy progress and prospects: Duchenne muscular dystrophy. Gene Ther 13:1677-1685
243. Alter J, Lou F, Rabinowitz A et al (2006) Systemic delivery of morpholino oligonucleotide restores dystrophin expression bodywide and improves dystrophic pathology. Nat Med 12:175-177
244. Cerletti M, Negri T, Cozzi F et al (2003) Dystrophic phenotype of canine X-linked muscular dystrophy is mitigated by adenovirus-mediated utrophin gene transfer. Gene Ther 10:750-757
245. Duan D (2006) Challenges and opportunities in dystrophin-deficient cardiomyopathy gene therapy. Hum Mol Genet 15 [Spec No 2]: R253-261
246. Goyenvalle A, Vulin A, Fougerousse F et al (2004) Rescue of dystrophic muscle through U7 snRNA-mediated exon skipping. Science 306:1796-1799
247. Gregorevic P, Blankinship MJ, Allen JM et al (2004) Systemic delivery of genes to striated muscles using adeno-associated viral vectors. Nat Med 10:828-834
248. Heemskerk H, De Winter CL, Van Ommen GJ et al (2009) Development of antisense-mediated exon skipping as a treatment for duchenne muscular dystrophy. Ann N Y Acad Sci 1175:71-79
249. Lu QL, Rabinowitz A, Chen YC et al (2005) Systemic delivery of antisense oligoribonucleotide restores dystrophin expression in body-wide skeletal muscles. Proc Natl Acad Sci U S A 102:198-203
250. Mendell JR, Rodino-Klapac LR, Rosales-Quintero X et al (2009) Limb-girdle muscular dystrophy type 2D gene therapy restores alpha-sarcoglycan and associated proteins. Ann Neurol 66:290-297
251. Nelson R (2004) Utrophin therapy for Duchenne muscular dystrophy? Lancet Neurol 3:637
252. Romero NB, Braun S, Benveniste O et al (2004) Phase I study of dystrophin plasmid-based gene therapy in Duchenne/Becker muscular dystrophy. Hum Gene Ther 15:1065-1076
253. Scott JM, Li S, Harper SQ et al (2002) Viral vectors for gene transfer of micro-, mini-, or fulllength dystrophin. Neuromuscul Disord 12 [Suppl 1]: S23-29
254. Van Deutekom JC, Janson AA, Ginjaar IB et al (2007) Local dystrophin restoration with antisense oligonucleotide PRO051. N Engl J Med 357:2677-2686
255. Wang Z, Zhu T, Qiao C et al (2005) Adeno-associated virus serotype 8 efficiently delivers genes to muscle and heart. Nat Biotechnol 23:321-328
256. Bolton-Maggs PH, Pasi KJ (2003) Haemophilias A and B. Lancet 361:1801-1809
257. Foster K, Foster H, Dickson JG (2006) Gene therapy progress and prospects: Duchenne muscular dystrophy. Gene Ther 13:1677-1685
258. Graw J, Brackmann HH, Oldenburg J et al (2005) Haemophilia A: from mutation analysis to new therapies. Nat Rev Genet 6:488-501
259. Hasbrouck NC, High KA (2008) AAV-mediated gene transfer for the treatment of hemophilia B: problems and prospects. Gene Ther 15:870-875
260. Mingozzi F, High KA (2007) Immune responses to AAV in clinical trials. Curr Gene Ther 7:316-324
261. Murphy SL, High KA (2008) Gene therapy for haemophilia. Br J Haematol 140:479-487
262. Jiang H, Pierce GF, Ozelo MC et al (2006) Evidence of multiyear factor IX expression by AAV-mediated gene transfer to skeletal muscle in an individual with severe hemophilia B. Mol Ther 14:452-455
263. Kay MA, Manno CS, Ragni MV et al (2000) Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an A AV vector. Nat Genet 24:257-261
264. Manno CS, Pierce GF, Arruda VR et al (2006) Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nat Med 12:342-347
265. Margaritis P, Roy E, Aljamali MN et al (2009) Successful treatment of canine hemophilia by continuous expression of canine FVIIa. Blood 113:3682-3689
266. Wang L, Nichols TC, Read MS et al (2000) Sustained expression of therapeutic level of factor IX in hemophilia B dogs by AAV-mediated gene therapy in liver. Mol Ther 1:154-158
267. Aghi M, Hochberg F, Breakefield XO (2000) Prodrug activation enzymes in cancer gene therapy. J Gene Med 2:148-164
268. Anderson RJ, Schneider J (2007) Plasmid DNA and viral vector-based vaccines for the treatment of cancer. Vaccine 25 [Suppl 2]: B24-34
269. Cattaneo R, Miest T, Shashkova EV, Barry MA (2008) Reprogrammed viruses as cancer therapeutics: targeted, armed and shielded. Nat Rev Micro 6:529-540
270. Heath WR, Belz GT, Behrens GMN et al (2004) Cross-presentation, dendritic cell subsets, and the generation of immunity to cellular antigens. Immunol Rev 199:9-26
271. Hermiston TW, Kirn DH (2005) Genetically based therapeutics for cancer: similarities and contrasts with traditional drug discovery and development. Mol Ther 11:496-507
272. June CH (2007) Adoptive T cell therapy for cancer in the clinic. J Clin Invest 117:1466-1476
273. June CH (2007) Principles of adoptive T cell cancer therapy. J Clin Invest 117:1204-1212
274. Larin SS, Georgiev GP, Kiselev SL (2004) Gene transfer approaches in cancer immunotherapy. Gene Ther 11 [Suppl 1]: S18-25
275. Liu TC, Kirn D (2008) Gene therapy progress and prospects cancer: oncolytic viruses. Gene Ther 15:877-884
276. McNeish IA, Bell SJ, Lemoine NR (2004) Gene therapy progress and prospects: cancer gene therapy using tumour suppressor genes. Gene Ther 11:497-503
277. Offringa R (2006) Cancer. Cancer immunotherapy is more than a numbers game. Science 314:68-69
278. Palmer DH, Young LS, Mautner V (2006) Cancer gene-therapy: clinical trials. Trends Biotechnol 24:76-82
279. Rice J, Ottensmeier CH, Stevenson FK (2008) DNA vaccines: precision tools for activating effective immunity against cancer. Nat Rev Cancer 8:108-120
280. Rossig C, Brenner MK (2004) Genetic modification of T lymphocytes for adoptive immunotherapy. Mol Ther 10:5-18
281. Bonini C, Ferrari G, Verzeletti S et al (1997) HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia. Science 276:1719-1724
282. Breckpot K, Aerts JL, Thielemans K (2007) Lentiviral vectors for cancer immunotherapy: transforming infectious particles into therapeutics. Gene Ther 14:847-862
283. Cesco-Gaspere M, Zentilin L, Giacca M, Burrone OR (2008) Boosting anti-idiotype immune response with recombinant AAV enhances tumour protection induced by gene gun vaccination. Scand J Immunol 68:58-66
284. Finke LH, Wentworth K, Blumenstein B et al (2007) Lessons from randomized phase III studies with active cancer immunotherapies: outcomes from the 2006 meeting of the Cancer Vaccine Consortium (CVC). Vaccine 25 [Suppl 2]: B97-B109
285. Folkman J, Watson K, Ingber D, Hanahan D (1989) Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature 339:58-61
286. Johnson LA, Morgan RA, Dudley ME et al (2009) Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood 114:535-546
287. McNeish IA, Bell SJ, Lemoine NR (2004) Gene therapy progress and prospects: cancer gene therapy using tumour suppressor genes. Gene Ther 11:497-503
288. Morgan RA, Dudley ME, Wunderlich JR et al (2006) Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 314:126-129
289. Nestle FO, Farkas A, Conrad C (2005) Dendritic-cell-based therapeutic vaccination against cancer. Curr Opin Immunol 17:163-169
290. Parmigiani RB, Bettoni F, Vibranovski MD et al (2006) Characterization of a cancer/testis (CT) antigen gene family capable of eliciting humoral response in cancer patients. Proc Natl Acad Sci U S A 103:18066-18071
291. Pulkkanen KJ, Yla-Herttuala S (2005) Gene therapy for malignant glioma: current clinical status. Mol Ther 12:585-598
292. Rapoport AP, Stadtmauer EA, Aqui N et al (2005) Restoration of immunity in lymphopenic individuals with cancer by vaccination and adoptive T-cell transfer. Nat Med 11:1230-1237
293. Ringdén O, Karlsson H, Olsson R et al (2009) The allogeneic graft-versus-cancer effect. Br J Haematol 147:614-633
294. Rosenberg SA, Aebersold P, Cornetta K et al (1990) Gene transfer into humans: immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction. N Engl J Med 323:570-578
295. Rosenthal R, Viehl CT, Guller U et al (2008) Active specific immunotherapy phase III trials for malignant melanoma: systematic analysis and critical appraisal. J Am Coll Surg 207:95-105
296. Tasciotti E, Zoppe M, Giacca M (2003) Transcellular transfer of active HSV-1 thymidine kinase mediated by an 11-amino-acid peptide from HIV-1 Tat. Cancer Gene Ther 10:64-74
297. Terando AM, Faries MB, Morton DL (2007) Vaccine therapy for melanoma: current status and future directions. Vaccine 25 [Suppl 2]: B4-16
298. Azzouz M (2006) Gene therapy for ALS: progress and prospects. Biochim Biophys Acta 1762:1122-1127
299. Baker D, Hankey DJ (2003) Gene therapy in autoimmune, demyelinating disease of the central nervous system. Gene Ther 10:844-853
300. Bradbury J (2005) Hope for AD with NGF gene-therapy trial. Lancet Neurol 4:335
301. Burton EA, Glorioso JC, Fink DJ (2003) Gene therapy progress and prospects: Parkinson's disease. Gene Ther 10:1721-1727
302. Choudry RB, Cudkowicz ME (2005) Clinical trials in amyotrophic lateral sclerosis: the tenuous past and the promising future. J Clin Pharmacol 45:1334-1344
303. Federici T, Boulis N (2007) Gene therapy for peripheral nervous system diseases. Curr Gene Ther 7:239-248
304. Fiandaca M, Forsayeth J, Bankiewicz K (2008) Current status of gene therapy trials for Parkinson's disease. Exp Neurol 209:51-57
305. Kaspar BK, Llado J, Sherkat N et al (2003) Retrograde viral delivery of IGF-1 prolongs survival in a mouse ALS model. Science 301:839-842
306. Mitchell JD, Borasio GD (2007) Amyotrophic lateral sclerosis. Lancet 369:2031-2041
307. Palfi S (2008) Towards gene therapy for Parkinson's disease. Lancet Neurol 7:375-376
308. Sheridan C (2007) Positive clinical data in Parkinson's and ischemia buoy gene therapy. Nat Biotechnol 25:823-824
309. Sumner CJ (2006) Therapeutics development for spinal muscular atrophy. NeuroRx 3:235-245
310. Tuszynski MH (2002) Growth-factor gene therapy for neurodegenerative disorders. Lancet Neurol 1:51-57
311. Zacchigna S, Giacca M (2009) Chapter 20: Gene therapy perspectives for nerve repair. Int Rev Neurobiol 87:381-392
312. Azzouz M, Le T, Ralph GS et al (2004) Lentivector-mediated SMN replacement in a mouse model of spinal muscular atrophy. J Clin Invest 114:1726-1731
313. Azzouz M, Ralph GS, Storkebaum E et al (2004) VEGF delivery with retrogradely transported lentivector prolongs survival in a mouse ALS model. Nature 429:413-417
314. Bloch J, Bachoud-Levi AC, Deglon N et al (2004) Neuroprotective gene therapy for Huntington's disease, using polymer-encapsulated cells engineered to secrete human ciliary neurotrophic factor: results of a phase I study. Hum Gene Ther 15:968-975
315. Christine CW, Starr PA, Larson PS et al (2009) Safety and tolerability of putaminal AADC gene therapy for Parkinson disease. Neurology 73:1662-1669
316. Eberling JL, Jagust WJ, Christine CW et al (2008) Results from a phase I safety trial of hAADC gene therapy for Parkinson disease. Neurology 70:1980-1983
317. Hua Y, Vickers TA, Okunola HL et al (2008) Antisense masking of an hnRNP A1/A2 intronic splicing silencer corrects SMN2 splicing in transgenic mice. Am J Hum Genet 82:834-848
318. Kaplitt MG, Feigin A, Tang C et al (2007) Safety and tolerability of gene therapy with an adenoassociated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial. Lancet 369:2097-2105
319. Kennington E (2009) Gene therapy delivers an alternative approach to Alzheimer's disease. Nat Rev Drug Discov 8:275
320. Lewis TB, Standaert DG (2008) Design of clinical trials of gene therapy in Parkinson disease. Exp Neurol 209:41-47
321. Mandel RJ, Burger C (2004) Clinical trials in neurological disorders using A AV vectors: promises and challenges. Curr Opin Mol Ther 6:482-490
322. Mandel RJ, Burger C, Snyder RO (2008) Viral vectors for in vivo gene transfer in Parkinson's disease: properties and clinical grade production. Exp Neurol 209:58-71
323. Nagahara AH, Merrill DA, Coppola G et al (2009) Neuroprotective effects of brain-derived neurotrophic factor in rodent and primate models of Alzheimer's disease. Nat Med 15:331-337
324. Ralph GS, Radcliffe PA, Day DM et al (2005) Silencing mutant SOD1 using RNAi protects against neurodegeneration and extends survival in an ALS model. Nat Med 11:429-433
325. Storkebaum E, Lambrechts D, Carmeliet P (2004) VEGF: once regarded as a specific angiogenic factor, now implicated in neuroprotection. Bioessays 26:943-954
326. Towne C, Schneider BL, Kieran D et al (2009) Efficient transduction of non-human primate motor neurons after intramuscular delivery of recombinant AAV serotype 6. Gene Ther 17:141-146
327. Tuszynski MH, Thal L, Pay M et al (2005) A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease. Nat Med 11:551-555
328. Bainbridge JW, Ali RR (2008) Success in sight: the eyes have it! Ocular gene therapy trials for LCA look promising. Gene Ther 15:1191-1192
329. Bainbridge JW, Tan MH, Ali RR (2006) Gene therapy progress and prospects: the eye. Gene Ther 13:1191-1197
330. Bennett J, Maguire AM (2000) Gene therapy for ocular disease. Mol Ther 1:501-505
331. Buch PK, Bainbridge JW, Ali RR (2008) AAV-mediated gene therapy for retinal disorders: from mouse to man. Gene Ther 15:849-857
332. Jager RD, Mieler WF, Miller JW (2008) Age-related macular degeneration. N Engl J Med 358:2606-2617
333. Kaiser J (2008) Gene therapy. Two teams report progress in reversing loss of sight. Science 320:606-607
334. Smith AJ, Bainbridge JW, Ali RR (2009) Prospects for retinal gene replacement therapy. Trends Genet 25:156-165
335. Acland GM, Aguirre GD, Ray J et al (2001) Gene therapy restores vision in a canine model of childhood blindness. Nat Genet 28:92-95
336. Bainbridge JW, Smith AJ, Barker SS et al (2008) Effect of gene therapy on visual function in Leber's congenital amaurosis. N Engl J Med 358:2231-2239
337. Dinculescu A, Glushakova L, Min SH, Hauswirth WW (2005) Adeno-associated virus-vectored gene therapy for retinal disease. Hum Gene Ther 16:649-663
338. Gehrs KM, Anderson DH, Johnson LV, Hageman GS (2006) Age-related macular degeneration: emerging pathogenetic and therapeutic concepts. Ann Med 38:450-471
339. Le Meur G, Stieger K, Smith AJ et al (2007) Restoration of vision in RPE65-deficient Briard dogs using an A AV serotype 4 vector that specifically targets the retinal pigmented epithelium. Gene Ther 14:292-303
340. Maguire AM, Simonelli F, Pierce EA et al (2008) Safety and efficacy of gene transfer for Leber's congenital amaurosis. N Engl J Med 358:2240-2248
341. Adams RH, Alitalo K (2007) Molecular regulation of angiogenesis and lymphangiogenesis. Nat Rev Mol Cell Biol 8:464-478
342. Augustin HG, Koh G Y, Thurston G, Alitalo K (2009) Control of vascular morphogenesis and homeostasis through the angiopoietin-Tie system. Nat Rev Mol Cell Biol 10:165-177
343. Bhargava B, Karthikeyan G, Abizaid AS, Mehran R (2003) New approaches to preventing restenosis. BMJ 327:274-279
344. Carmeliet P (2005) Angiogenesis in life, disease and medicine. Nature 438:932-936
345. Crook MF, Akyurek LM (2003) Gene transfer strategies to inhibit neointima formation. Trends Cardiovasc Med 13:102-106
346. Giacca M (2007) Virus-mediated gene transfer to induce therapeutic angiogenesis: where do we stand? Int J Nanomed 2:527-540
347. Olsson AK, Dimberg A, Kreuger J, Claesson-Welsh L (2006) VEGF receptor signalling: in control of vascular function. Nat Rev Mol Cell Biol 7:359-371
348. Rissanen TT, Yla-Herttuala S (2007) Current status of cardiovascular gene therapy. Mol Ther 15:1233-1247
349. Stewart S, MacIntyre K, Hole DJ et al (2001) More 'malignant' than cancer? Five-year survival following a first admission for heart failure. Eur J Heart Fail 3:315-322
350. Vincent KA, Jiang C, Boltje I, Kelly RA (2007) Gene therapy progress and prospects: therapeutic angiogenesis for ischemic cardiovascular disease. Gene Ther 14:781-789
351. Vinge LE, Raake PW, Koch WJ (2008) Gene therapy in heart failure. Circ Res 102:1458-1470
352. Yancopoulos GD, Davis S, Gale NW et al (2000) Vascular-specific growth factors and blood vessel formation. Nature 407:242-248
353. Yla-Herttuala S, Alitalo K (2003) Gene transfer as a tool to induce therapeutic vascular growth. Nat Med 9:694-701
354. Yla-Herttuala S, Markkanen JE, Rissanen TT (2004) Gene therapy for ischemic cardiovascular diseases: some lessons learned from the first clinical trials. Trends Cardiovasc Med 14:295-300
355. Yla-Herttuala S, Martin JF (2000) Cardiovascular gene therapy. Lancet 355:213-222
356. Arsic N, Zacchigna S, Zentilin L et al (2004) Vascular endothelial growth factor stimulates skeletal muscle regeneration in vivo. Mol Ther 10:844-854
357. Arsic N, Zentilin L, Zacchigna S et al (2003) The biology of VEGF and its receptors. Nat Med 9:669-676
358. Baumgartner I, Pieczek A, Manor O et al (1998) Constitutive expression of phVEGF165 after intramuscular gene transfer promotes collateral vessel development in patients with critical limb ischemia. Circulation 97:1114-1123
359. Del Monte F, Harding SE, Schmidt U et al (1999) Restoration of contractile function in isolated cardiomyocytes from failing human hearts by gene transfer of SERCA2a. Circulation 100:2308-2311
360. Ferrarini M, Arsic N, Recchia FA et al (2006) Adeno-associated virus-mediated transduction of VEGF165 improves cardiac tissue viability and functional recovery after permanent coronary occlusion in conscious dogs. Circ Res 98:954-961
361. Grines CL, Watkins MW, Helmer G et al (2002) Angiogenic Gene Therapy (AGENT) trial in patients with stable angina pectoris. Circulation 105:1291-1297
362. Inagaki K, Fuess S, Storm TA et al (2006) Robust systemic transduction with AAV9 vectors in mice: efficient global cardiac gene transfer superior to that of AAV8. Mol Ther 14:45-53
363. Lafont A, Guerot C, Lemarchand P (1995) Which gene for which restenosis? Lancet 346:1442-1443
364. Melo LG, Pachori AS, Kong D et al (2004) Gene and cell-based therapies for heart disease. FASEB J 18:648-663
365. Simons M, Bonow RO, Chronos NA et al (2000) Clinical trials in coronary angiogenesis: issues, problems, consensus: an expert panel summary. Circulation 102:E73-E86
366. Sinagra G, Giacca M (2003) Induction of functional neovascularization by combined VEGF and angiopoietin-1 gene transfer using AAV vectors. Mol Ther 7:450-459
367. Tafuro S, Ayuso E, Zacchigna S et al (2009) Inducible adeno-associated virus vectors promote functional angiogenesis in adult organisms via regulated vascular endothelial growth factor expression. Cardiovasc Res 83:663-671
368. Vale PR, Losordo DW, Milliken CE et al (2000) Left ventricular electromechanical mapping to assess efficacy of phVEGF (165) gene transfer for therapeutic angiogenesis in chronic myocardial ischemia. Circulation 102:965-974
369. Zacchigna S, Tasciotti E, Kusmic C et al (2007) In vivo imaging shows abnormal function of vascular endothelial growth factor-induced vasculature. Hum Gene Ther 18:515-524
370. Baltimore D (1988) Gene therapy. Intracellular immunization. Nature 335:395-396
371. Dropulic B, June CH (2006) Gene-based immunotherapy for human immunodeficiency virus infection and acquired immunodeficiency syndrome. Hum Gene Ther 17:577-588
372. Fillat C, Carrio M, Cascante A, Sangro B (2003) Suicide gene therapy mediated by the Herpes Simplex virus thymidine kinase gene/Ganciclovir system: fifteen years of application. Curr Gene Ther 3:13-26
373. Giacca M (2008) Gene therapy to induce cellular resistance to HIV-1 infection: lessons from clinical trials. Adv Pharmacol 56:297-325
374. Haasnoot J, Westerhout EM, Berkhout B (2007) RNA interference against viruses: strike and counterstrike. Nat Biotechnol 25:1435-1443
375. Manilla P, Rebello T, Afable C et al (2005) Regulatory considerations for novel gene therapy products: a review of the process leading to the first clinical lentiviral vector. Hum Gene Ther 16:17-25
376. Morris K. V, Rossi JJ (2006) Lentiviral-mediated delivery of siRNAs for antiviral therapy. Gene Ther 13:553-558
377. Rossi JJ (2006) RNAi as a treatment for HIV-1 infection. Biotechniques [Suppl]: 25-29
378. Rossi JJ, June CH, Kohn DB (2007) Genetic therapies against HIV. Nat Biotechnol 25:1444-1454
379. Strayer DS, Akkina R, Bunnell BA et al (2005) Current status of gene therapy strategies to treat HIV/AIDS. Mol Ther 11:823-842
380. Wolkowicz R, Nolan GP (2005) Gene therapy progress and prospects: novel gene therapy approaches for AIDS. Gene Ther 12:467-476
381. Buchbinder SP, Mehrotra D V, Duerr A et al (2008) Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-ofconcept trial. Lancet 372:1881-1893
382. Das AT, Brummelkamp TR, Westerhout EM et al (2004) Human immunodeficiency virus type 1 escapes from RNA interference-mediated inhibition. J Virol 78:2601-2605
383. Levine BL, Humeau LM, Boyer J et al (2006) Gene transfer in humans using a conditionally replicating lentiviral vector. Proc Natl Acad Sci U S A 103:17372-17377
384. Li MJ, Kim J, Li S et al (2005) Long-term inhibition of HIV-1 infection in primary hematopoietic cells by lentiviral vector delivery of a triple combination of anti-HIV shRNA, anti-CCR5 ribozyme, and a nucleolar-localizing TAR decoy. Mol Ther 12:900-909
385. Mitsuyasu RT, Merigan TC, Carr A et al (2009) Phase 2 gene therapy trial of an anti-HIV ribozyme in autologous CD34+ cells. Nat Med 15:285-292
386. Morgan RA, Walker R (1996) Gene therapy for AIDS using retroviral mediated gene transfer to deliver HIV-1 antisense TAR and transdominant Rev protein genes to syngeneic lymphocytes in HIV-1 infected identical twins. Hum Gene Ther 7:1281-1306
387. Nisole S, Stoye JP, Saib A (2005) TRIM family proteins: retroviral restriction and antiviral defence. Nat Rev Microbiol 3:799-808
388. Novina CD, Murray MF, Dykxhoorn DM et al (2002) siRNA-directed inhibition of HIV-1 infection. Nat Med 8:681-686
389. Poeschla E, Corbeau P, Flossie W-S (1996) Development of HIV vectors for anti-HIV gene therapy. Proc Natl Acad Sci U S A 93:11395-11399
390. Rondon IJ, Marasco WA (1997) Intracellular antibodies (intrabodies) for gene therapy of infectious diseases. Annu Rev Microbiol 51:257-283
391. Sarver N, Cantin EM, Chang PS et al (1990) Ribozymes as potential anti-HIV-1 therapeutic agents. Science 247:1222-1225
392. Schambach A, Schiedlmeier B, Kuhlcke K et al (2006) Towards hematopoietic stem cell-mediated protection against infection with human immunodeficiency virus. Gene Ther 13:1037-1047
393. Ter Brake O, Konstantinova P, Ceylan M, Berkhout B (2006) Silencing of HIV-1 with RNA interference: a multiple shRNA approach. Mol Ther 14:883-892
394. Westerhout EM, Ooms M, Vink M et al (2005) HIV-1 can escape from RNA interference by evolving an alternative structure in its RNA genome. Nucleic Acids Res 33:796-804
395. Broedl UC, Rader DJ (2005) Gene therapy for lipoprotein disorders. Exp Opin Biol Ther 5:1029-1038
396. Nguyen TH, Ferry N (2004) Liver gene therapy: advances and hurdles. Gene Ther 11 [Suppl 1]: S76-84
397. Nguyen TH, Mainot S, Lainas P et al (2009) Ex vivo liver-directed gene therapy for the treatment of metabolic diseases: advances in hepatocyte transplantation and retroviral vectors. Curr Gene Ther 9:136-149
398. Stecenko AA, Brigham KL (2003) Gene therapy progress and prospects: alpha-1 antitrypsin. Gene Ther 10:95-99
399. Wood AM, Stockley RA (2007) Alpha one antitrypsin deficiency: from gene to treatment. Respiration 74:481-492
400. Grossman M, Rader DJ, Muller DW et al (1995) A pilot study of ex vivo gene therapy for homozygous familial hypercholesterolaemia. Nat Med 1:1148-1154
401. Grossman M, Raper SE, Kozarsky K et al (1994) Successful ex vivo gene therapy directed to liver in a patient with familial hypercholesterolaemia. Nat Genet 6:335-341
402. Kozarsky KF, Jooss K, Donahee M et al (1996) Effective treatment of familial hypercholester - olaemia in the mouse model using adenovirus-mediated transfer of the VLDL receptor gene. Nat Genet 13:54-62
403. Miranda PS, Bosma PJ (2009) Towards liver-directed gene therapy for Crigler-Najjar syndrome. Curr Gene Ther 9:72-82
404. Stoller JK, Aboussouan LS (2005) Alpha1-antitrypsin deficiency. Lancet 365:2225-2236
405. Caplan AL (2008) If it's broken, shouldn't it be fixed? Informed consent and initial clinical trials of gene therapy. Hum Gene Ther 19:5-6
406. Chan S, Harris J (2006) Cognitive regeneration or enhancement: the ethical issues. Regen Med 1:361-366
407. Chan S, Harris J (2006) The ethics of gene therapy. Curr Opin Mol Ther 8:377-383
408. Coutelle C, Themis M, Waddington SN et al (2005) Gene therapy progress and prospects: fetal gene therapy - first proofs of concept - some adverse effects. Gene Ther 12:1601-1607
409. Deakin CT, Alexander IE, Kerridge I (2009) Accepting risk in clinical research: is the gene therapy field becoming too risk-averse? Mol Ther 17:1842-1848
410. Harris J, Chan S (2008) Enhancement is good for you!: understanding the ethics of genetic enhancement. Gene Ther 15:338-339
411. Kahn J (2008) Informed consent in human gene transfer clinical trials. Hum Gene Ther 19:7-8
412. Kiuru M, Crystal RG (2008) Progress and prospects: gene therapy for performance and appearance enhancement. Gene Ther 15:329-337
413. Spink J, Geddes D (2004) Gene therapy progress and prospects: bringing gene therapy into medical practice: the evolution of international ethics and the regulatory environment. Gene Ther 11:1611-1616
414. Wells DJ (2008) Gene doping: the hype and the reality. Br J Pharmacol 154:623-631
415. Batshaw ML, Wilson JM, Raper S et al (1999) Recombinant adenovirus gene transfer in adults with partial ornithine transcarbamylase deficiency (OTCD). Hum Gene Ther 10:2419-2437
416. Frank KM, Hogarth DK, Miller JL et al (2009) Investigation of the cause of death in a gene-therapy trial. N Engl J Med 361:161-169
417. Grimm D, Streetz KL, Jopling CL et al (2006) Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways. Nature 441:537-541
418. Kaiser J (2007) Clinical research. Death prompts a review of gene therapy vector. Science 317:580
419. Reay DP, Bilbao R, Koppanati BM et al (2008) Full-length dystrophin gene transfer to the mdx mouse in utero. Gene Ther 15:531-536